Medication<unk> 's cardio physiology typically presents as an (antidromic) AV reentrant tachycardia with associated pre-excitation. In this setting, the preferred medication treatment agent is procainamide. Since AV-blockade may promote conduction over the accessory pathway, drugs such as beta blockers, calcium channel blockers, and digoxin are contraindicated. If atrial fibrillation with pre-excitation occurs, treatment options include procainamide, flecainide, propafenone, dofetilide, and ibutilide, since these medications slow conduction in the accessory pathway causing the tachycardia and should be administered before considering electrical cardioversion. Intravenous amiodarone may also convert atrial fibrillation and/or slow the ventricular response. Surgery The Canadian Cardiovascular Society (CCS) recommends surgical intervention for these indications: * Limited exercise capacity (NYHA III-IV) * Increasing heart size (cardiothoracic ratio greater than 65%) * Important cyanosis (resting oxygen saturation less than 90% - level B) * Severe tricuspid regurgitation with symptoms * Transient ischemic attack or stroke The CCS further recommends patients who require operation for<unk>  should be operated on by congenital heart surgeons who have substantial specific experience and success with this operation. Every effort should be made to preserve the native tricuspid valve.
Ebstein's anomaly
Tetralogy of Fallot  Tetralogy of Fallot  1
Jordans' anomaly
First arch syndrome
Choanal atresia
Double aortic arch
Pulmonary atresia
May–Hegglin anomaly